human hepatitis b immunoglobulin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
human hepatitis b immunoglobulin: clinical details
Prescribing considerations
- Confirm the product-specific licensed indication and route; Zutectra is not licensed for post-exposure prophylaxis.
- For transplant prophylaxis, confirm relevant HBsAg and HBV-DNA status and coordinate with the specialist antiviral plan.
- Assess previous immunoglobulin reactions, IgA deficiency and anti-IgA antibodies.
- For intravenous treatment, assess hydration, renal and thrombotic risk and use an appropriate monitored infusion rate.
- Record the product name and batch number for traceability.
- Passive antibodies can cause misleading positive serology and interfere with red-cell antibody testing.
Contraindications and cautions
- Hypersensitivity to human hepatitis B immunoglobulin, human immunoglobulins or a product excipient
- Selective IgA deficiency with anti-IgA antibodies where an IgA-containing product risks anaphylaxis
- Zutectra must not be administered intravascularly
Monitoring
- Observe for hypersensitivity during and after administration.
- Monitor serum anti-HBs concentrations during continuing or transplant prophylaxis.
- For intravenous treatment, assess renal function, urine output and hydration where clinically appropriate.
- Monitor patients at increased risk of thrombosis, haemolysis, neutropenia or pulmonary reactions.
- Continue relevant virological surveillance after liver transplantation and document adherence with home administration.
Clinical pharmacology
The active component is mainly IgG enriched with antibodies to hepatitis B surface antigen. Intravenous administration provides immediate systemic availability; subcutaneous administration is absorbed more gradually. IgG and immune complexes are cleared through the reticuloendothelial system.
Formulation and product differences
- Hepatect CP is a ready-to-use intravenous solution in vials with broader licensed immunoprophylaxis and transplant indications.
- Zutectra is a single-use, pre-filled subcutaneous syringe licensed for selected HBsAg-negative and HBV-DNA-negative adults after liver transplantation.
- Zutectra may be administered at home by a trained patient or caregiver under specialist monitoring; Hepatect CP is administered by intravenous infusion.
- Both contain glycine and water for injections, but their IgA content, concentration, presentation and route differ.
human hepatitis b immunoglobulin preparations and strengths
Injection
Route: Parenteral
Strengths: 500 units
human hepatitis b immunoglobulin interactions
Tell the clinical team about recent or planned vaccinations and all other medicines.
Live attenuated vaccines, including measles, mumps, rubella and varicella
Transferred antibodies may reduce the vaccine response, so vaccination timing or later revaccination may need specialist adjustment. Interference with measles vaccination can persist longer.
Loop diuretics
Concomitant use should be avoided with intravenous Hepatect CP because of concerns including renal complications.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.